Quarterly ResultMay 7, 2026, 07:07 AM
Iovance 1Q26 Revenue $71M, +45% YoY; 40% cORR Endometrial Cancer
AI Summary
Iovance Biotherapeutics reported first quarter 2026 total revenue of ~$71 million, marking a ~45% year-over-year increase, with U.S. Amtagvi revenue at ~$60 million. The company provided strong guidance, expecting 2Q26 revenue between $86 million and $88 million, and full-year 2026 revenue of $350 million to $370 million. Additionally, Iovance announced positive initial data for lifileucel in metastatic serous endometrial cancer, showing a 40% confirmed objective response rate. The company is accelerating Amtagvi adoption and commercial expansion, advancing multiple clinical trials, and reported a 12% decrease in R&D expenses compared to 4Q25. Dr. Friedrich Graf Finckenstein, Chief Medical Officer, will retire in June 2026.
Key Highlights
- 1Q26 Total Revenue was ~$71 million, a ~45% increase year-over-year.
- 2Q26 Revenue Guidance is $86 million to $88 million.
- FY26 Revenue Guidance is $350 million to $370 million.
- Amtagvi U.S. revenue was ~$60 million in 1Q26.
- Lifileucel showed a 40% confirmed objective response rate in metastatic serous endometrial cancer.
- Research and Development expenses decreased by 12% compared to 4Q25.
- Cash, cash equivalents, and investments totaled ~$319 million as of March 31, 2026.
- Amtagvi turnaround time is 32 days or less for TIL therapy.